Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
Ajani JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S.
Ajani JA, et al. Among authors: ding s.
Br J Cancer. 2018 Jan;118(1):52-61. doi: 10.1038/bjc.2017.388. Epub 2017 Nov 14.
Br J Cancer. 2018.
PMID: 29136404
Free PMC article.